A Retrospective Review of Anthralin in Petrolatum in the Treatment of Alopecia Areata in the Pediatric Population

This review found that topical immunotherapy and light/laser therapy may achieve over 50% hair regrowth efficacy in treating extensive alopecia areata in children, with no serious side effects observed.

This study found that topical corticosteroids are the most supported first-line treatment for pediatric alopecia areata, with contact immunotherapy as the next best option.

In this case report, the authors describe a child with treatment-resistant alopecia areata who successfully responded to leflunomide and anthralin, proposing this combination as a potentially cost-effective alternative for managing recalcitrant cases by possibly inhibiting the JAK/STAT pathway.

This study found that 1% anthralin ointment effectively promoted hair growth in children with chronic, severe alopecia areata, showing complete or partial responses in 70% of participants over 12 months, without serious adverse events.

This study found that combination therapy with diphenylcyclopropenone and anthralin was more effective for complete hair regrowth in chronic extensive alopecia areata than diphenylcyclopropenone alone, despite more common side effects.

This article reviews anthralin's pharmacology, mode of action, and its use for psoriasis and other dermatoses, but reports no new clinical results.

This review analyzed randomized controlled trials on alopecia areata treatment and found that while several treatments showed effectiveness, most studies had limitations affecting their interpretability.

This study found that topical clobetasol propionate cream provided a modest improvement in hair regrowth for alopecia areata patients, though those with atopy had higher relapse rates after treatment completion.

This pilot study found that azelaic acid treatment for patchy alopecia areata had similar hair regrowth results as anthralin, suggesting it may be an effective topical therapy.

These guidelines for alopecia areata management, prepared by the British Association of Dermatologists, provide evidence-based treatment recommendations and insights into the condition's epidemiology, diagnosis, and investigation.

This study found that anthralin and mechlorethamine were the most effective therapies among those tested in AA-affected rodent models, providing a basis for further analysis of their mechanisms in Alopecia Areata.

In this study, 0.5%-1.0% anthralin cream led to a cosmetic response in 25% of patients with severe alopecia areata, despite common side effects like pruritus and erythema.